Resistance management of Alpelisib-Piqray

Alpelisib (Alpelisib)-Piqray is a therapeutic drug for breast cancer that blocks the growth and spread of tumor cells by inhibiting the PI3K signaling pathway. However, some patients may develop drug resistance after treatment with apelvis. If the patient develops drug resistance, the dose of apelix may be adjusted or other treatment options may be considered. This may require a detailed discussion with your doctor to determine the best adjustment.

Apelvis is often given in combination with an anti-estrogen drug, such as fulvestrant, to treat breast cancer. Combination therapy is another way to deal with drug resistance, and one can try to combine apelvis with other anticancer drugs or targeted therapies to enhance the therapeutic effect. Mechanisms of resistance may vary from person to person, so individualized treatment options may be more effective. Through technologies such as molecular testing, it is possible to determine the specific mechanisms leading to drug resistance and then select a personalized treatment strategy. If standard treatments are ineffective, patients may consider participating in relevant clinical trials. These trials may involve new drugs, treatment regimens or targeted treatment strategies to provide more treatment options for drug-resistant patients.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.